EA029283B1 - Антагонисты il-17a - Google Patents
Антагонисты il-17a Download PDFInfo
- Publication number
- EA029283B1 EA029283B1 EA201290254A EA201290254A EA029283B1 EA 029283 B1 EA029283 B1 EA 029283B1 EA 201290254 A EA201290254 A EA 201290254A EA 201290254 A EA201290254 A EA 201290254A EA 029283 B1 EA029283 B1 EA 029283B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- zeg
- tug
- antibody
- azr
- amino acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25686209P | 2009-10-30 | 2009-10-30 | |
US31091910P | 2010-03-05 | 2010-03-05 | |
PCT/US2010/054662 WO2011053763A2 (fr) | 2009-10-30 | 2010-10-29 | Antagonistes de l'il-17a |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201290254A1 EA201290254A1 (ru) | 2012-12-28 |
EA029283B1 true EA029283B1 (ru) | 2018-03-30 |
Family
ID=43922991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201290254A EA029283B1 (ru) | 2009-10-30 | 2010-10-29 | Антагонисты il-17a |
Country Status (21)
Country | Link |
---|---|
US (1) | US8519107B2 (fr) |
EP (1) | EP2493506B1 (fr) |
JP (1) | JP5922025B2 (fr) |
KR (1) | KR101836217B1 (fr) |
CN (1) | CN102905727B (fr) |
AU (1) | AU2010313304B2 (fr) |
BR (1) | BR112012010280B1 (fr) |
CA (1) | CA2779257C (fr) |
CL (1) | CL2012001141A1 (fr) |
CO (1) | CO6541541A2 (fr) |
CR (1) | CR20120298A (fr) |
EA (1) | EA029283B1 (fr) |
EC (1) | ECSP12011871A (fr) |
ES (1) | ES2728115T3 (fr) |
GT (1) | GT201200132A (fr) |
IL (1) | IL219390B (fr) |
MX (1) | MX2012005086A (fr) |
NI (1) | NI201200080A (fr) |
NZ (1) | NZ599737A (fr) |
PE (1) | PE20121363A1 (fr) |
WO (1) | WO2011053763A2 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG175276A1 (en) | 2009-05-05 | 2011-11-28 | Novimmune Sa | Anti-il-17f antibodies and methods of use thereof |
EP2571901B1 (fr) | 2010-05-20 | 2019-01-02 | Ablynx N.V. | Matériaux biologiques associés à her3 |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
WO2013116682A1 (fr) | 2012-02-02 | 2013-08-08 | Ensemble Therapeutics Corporation | Composés macrocycliques pour une modulation d'il-17 |
CN103509118B (zh) * | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
WO2014001368A1 (fr) * | 2012-06-25 | 2014-01-03 | Orega Biotech | Anticorps antagonistes de l'il-17 |
CA3185317A1 (fr) | 2013-02-08 | 2014-08-14 | Novartis Ag | Anticorps anti-il-17a et leur utilisation dans le traitement de troubles auto-immuns et inflammatoires |
ES2818074T3 (es) * | 2013-11-18 | 2021-04-09 | Shanghai hengrui pharmaceutical co ltd | Agente de unión a IL-17A y sus usos |
WO2015127405A2 (fr) | 2014-02-21 | 2015-08-27 | Genentech, Inc. | Anticorps bispécifiques anti-il-13/il-17 et leurs utilisations |
CN103936854B (zh) * | 2014-04-30 | 2016-08-17 | 北京精益泰翔技术发展有限公司 | 抗il-17a单克隆抗体及其制备与应用 |
US10799584B2 (en) | 2014-06-09 | 2020-10-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents |
WO2015191568A2 (fr) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Polythérapies utilisant des agents qui ciblent des stromas associés à une tumeur ou des cellules tumorales et la vasculature tumorale |
WO2015191617A2 (fr) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Polythérapies utilisant des anti-métabolites et des agents qui ciblent un stroma associé à une tumeur ou des cellules tumorales |
US11033620B2 (en) | 2014-06-09 | 2021-06-15 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules |
US10758526B2 (en) | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways |
WO2015191602A2 (fr) * | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Polythérapies ciblant un stroma associé à une tumeur ou des cellules tumorales |
US10758614B2 (en) | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase |
US10434174B2 (en) | 2014-06-09 | 2019-10-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
CA2970759A1 (fr) * | 2014-12-15 | 2016-06-23 | Morphosys Ag | Anticorps anti-il-17 c |
CN107407677B (zh) * | 2015-01-28 | 2020-07-17 | 豪夫迈·罗氏有限公司 | 多发性硬化的基因表达标志和治疗 |
CN105315371B (zh) * | 2015-03-05 | 2018-05-29 | 北京百特美博生物科技有限公司 | 抗人il-17单克隆抗体 |
CN106336459B (zh) * | 2015-07-13 | 2020-12-08 | 三生国健药业(上海)股份有限公司 | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 |
US20170218092A1 (en) * | 2016-01-28 | 2017-08-03 | Janssen Biotech, Inc. | Bispecific Anti-TNF-Alpha/IL17A Antibodies and Anti-TNF-Alpha Antibodies and Methods of Their Use |
AU2017250191A1 (en) * | 2016-04-13 | 2018-11-08 | Orimabs Ltd. | Anti-PSMA antibodies and use thereof |
ES2905917T3 (es) * | 2016-09-14 | 2022-04-12 | Beijing Hanmi Pharmaceutical Co Ltd | Anticuerpo que se une específicamente a IL-17A y fragmento funcional del mismo |
CN108359011B (zh) * | 2017-07-21 | 2019-06-25 | 华博生物医药技术(上海)有限公司 | 靶向于白介素17a的抗体、其制备方法和应用 |
JP2021519589A (ja) * | 2018-03-29 | 2021-08-12 | アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc | インターロイキン17a(il−17a)に結合する抗体を用いた自己免疫障害及び炎症障害の治療 |
CA3100092A1 (fr) * | 2018-05-17 | 2019-11-21 | Jiangsu Qyuns Therapeutics Co., Ltd. | Anticorps monoclonal anti-interleukine 17a humaine et son application |
CN111303283A (zh) * | 2018-12-12 | 2020-06-19 | 上海君实生物医药科技股份有限公司 | 抗il-17a抗体及其应用 |
EP3689907A1 (fr) * | 2019-01-31 | 2020-08-05 | Numab Therapeutics AG | Anticorps dirigés contre il-17a et leurs procédés d'utilisation |
WO2021018191A1 (fr) * | 2019-07-30 | 2021-02-04 | 江苏恒瑞医药股份有限公司 | Méthode de traitement d'une maladie auto-immune par un antagoniste de l'il-17 |
MX2022003815A (es) | 2019-09-30 | 2022-05-06 | Janssen Pharmaceutica Nv | Composiciones y metodos para un ensayo de acoplamiento diana de il-17 con moduladores de molecula peque?a. |
JP2022549464A (ja) | 2019-09-30 | 2022-11-25 | ヤンセン ファーマシューティカ エヌ.ベー. | 大分子モジュレータを用いたil-17標的結合アッセイのための組成物及び方法 |
IT202200016722A1 (it) * | 2022-08-04 | 2024-02-04 | Paolo Grieco | Nuovo peptide derivato da interleuchina-17A (IL-17A) e anticorpo neutralizzante (Ab17-IPL-1) |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026667A1 (fr) * | 1998-10-30 | 2000-05-11 | Miller Jonathan L | Regions variables de chaine lourde et de chaine legere d'anticorps diriges contre la glycoproteine plaquettaire humaine ib alpha |
US20020086014A1 (en) * | 1999-08-24 | 2002-07-04 | Korman Alan J. | Human CTLA-4 antibodies and their uses |
US20030099647A1 (en) * | 2001-10-05 | 2003-05-29 | Deshpande Rajendra V. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US20050150002A1 (en) * | 2004-01-02 | 2005-07-07 | Dellapenna Dean | Novel carotenoid hydroxylases for use in engineering carotenoid metabolism in plants |
US20050208558A1 (en) * | 1999-10-19 | 2005-09-22 | Applera Corporation | Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof |
WO2007076524A2 (fr) * | 2005-12-29 | 2007-07-05 | Centocor, Inc. | Anticorps humains anti-il-23, compositions, procedes et utilisations afferents |
US20070271630A1 (en) * | 2005-02-24 | 2007-11-22 | Boukharov Andrey A | Methods for genetic control of plant pest infestation and compositions thereof |
US20080095775A1 (en) * | 2006-06-13 | 2008-04-24 | Lewis Katherine E | Il-17 and il-23 antagonists and methods of using the same |
US20080095770A1 (en) * | 2006-08-09 | 2008-04-24 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US20090105461A1 (en) * | 2004-03-15 | 2009-04-23 | Wyeth | Calicheamicin conjugates |
US20090175881A1 (en) * | 2006-08-11 | 2009-07-09 | Presta Leonard G | Antibodies to il-17a |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO1988007089A1 (fr) | 1987-03-18 | 1988-09-22 | Medical Research Council | Anticorps alteres |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
ES2087997T3 (es) | 1990-01-12 | 1996-08-01 | Cell Genesys Inc | Generacion de anticuerpos xenogenicos. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994004679A1 (fr) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5885793A (en) | 1991-12-02 | 1999-03-23 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
TWI313299B (en) | 2000-11-30 | 2009-08-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
JP4406206B2 (ja) * | 2001-04-24 | 2010-01-27 | バイエル コーポレーション | ヒトtimp−1抗体 |
WO2002102973A2 (fr) * | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Anticorps bloquant l'activation de proteine tyrosine kinase recepteur, procedes de criblage et utilisations |
US6649055B1 (en) | 2002-05-07 | 2003-11-18 | The United States Of America As Represented By The United States Department Of Energy | Pump station for radioactive waste water |
US7501247B2 (en) | 2004-05-03 | 2009-03-10 | Schering Corporation | Method of treating skin inflammation |
JP2008501035A (ja) | 2004-05-28 | 2008-01-17 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 妊孕性関連障害の治療におけるil−17の使用 |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
GB0525214D0 (en) * | 2005-12-12 | 2006-01-18 | Bioinvent Int Ab | Biological materials and uses thereof |
AU2006325860B2 (en) | 2005-12-13 | 2011-09-22 | Eli Lilly And Company | Anti-IL-17 antibodies |
CA2646478A1 (fr) * | 2006-03-10 | 2007-09-20 | Zymogenetics, Inc. | Anticorps se liant a la fois avec il-17a et il-17f et procedes d'utilisation |
TW200815469A (en) | 2006-06-23 | 2008-04-01 | Astrazeneca Ab | Compounds |
GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
WO2009003096A2 (fr) | 2007-06-26 | 2008-12-31 | Centocor, Inc. | Mutéines il-17, anticorps, compositions, procédés et utilisations |
DE112008003232T5 (de) | 2007-11-30 | 2011-02-24 | Glaxo Group Limited, Greenford | Antigen-Bindungskonstrukte |
WO2009082624A2 (fr) * | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonistes de il-17a, il-17f et il-23 et procédés d'utilisation de ceux-ci |
CA2710373A1 (fr) * | 2007-12-19 | 2009-07-09 | Ping Tsui | Conception et generation de banques d'exposition sur phage humain pix de novo au moyen d'une fusion vers pix ou pvii, vecteur, anticorps et procedes |
GB0807413D0 (en) | 2008-04-23 | 2008-05-28 | Ucb Pharma Sa | Biological products |
CN102617735B (zh) | 2008-09-29 | 2015-09-09 | 罗氏格黎卡特股份公司 | 针对人il17的抗体及其应用 |
WO2010045340A1 (fr) | 2008-10-14 | 2010-04-22 | Centocor Ortho Biotech Inc. | Procédés d’humanisation et de maturation d’affinité d’anticorps |
-
2010
- 2010-10-29 KR KR1020127013837A patent/KR101836217B1/ko active IP Right Grant
- 2010-10-29 US US12/915,445 patent/US8519107B2/en active Active
- 2010-10-29 CN CN201080059869.3A patent/CN102905727B/zh active Active
- 2010-10-29 EP EP10827516.5A patent/EP2493506B1/fr active Active
- 2010-10-29 NZ NZ599737A patent/NZ599737A/en unknown
- 2010-10-29 MX MX2012005086A patent/MX2012005086A/es active IP Right Grant
- 2010-10-29 WO PCT/US2010/054662 patent/WO2011053763A2/fr active Application Filing
- 2010-10-29 ES ES10827516T patent/ES2728115T3/es active Active
- 2010-10-29 BR BR112012010280-0A patent/BR112012010280B1/pt active IP Right Grant
- 2010-10-29 EA EA201290254A patent/EA029283B1/ru unknown
- 2010-10-29 CA CA2779257A patent/CA2779257C/fr active Active
- 2010-10-29 AU AU2010313304A patent/AU2010313304B2/en active Active
- 2010-10-29 PE PE2012000591A patent/PE20121363A1/es not_active Application Discontinuation
- 2010-10-29 JP JP2012537102A patent/JP5922025B2/ja active Active
-
2012
- 2012-04-24 IL IL219390A patent/IL219390B/en active IP Right Grant
- 2012-04-27 NI NI201200080A patent/NI201200080A/es unknown
- 2012-04-30 CL CL2012001141A patent/CL2012001141A1/es unknown
- 2012-04-30 GT GT201200132A patent/GT201200132A/es unknown
- 2012-05-03 CO CO12072188A patent/CO6541541A2/es unknown
- 2012-05-12 EC ECSP12011871 patent/ECSP12011871A/es unknown
- 2012-05-30 CR CR20120298A patent/CR20120298A/es unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000026667A1 (fr) * | 1998-10-30 | 2000-05-11 | Miller Jonathan L | Regions variables de chaine lourde et de chaine legere d'anticorps diriges contre la glycoproteine plaquettaire humaine ib alpha |
US20020086014A1 (en) * | 1999-08-24 | 2002-07-04 | Korman Alan J. | Human CTLA-4 antibodies and their uses |
US20050208558A1 (en) * | 1999-10-19 | 2005-09-22 | Applera Corporation | Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US20030099647A1 (en) * | 2001-10-05 | 2003-05-29 | Deshpande Rajendra V. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
US20050150002A1 (en) * | 2004-01-02 | 2005-07-07 | Dellapenna Dean | Novel carotenoid hydroxylases for use in engineering carotenoid metabolism in plants |
US20090105461A1 (en) * | 2004-03-15 | 2009-04-23 | Wyeth | Calicheamicin conjugates |
US20070271630A1 (en) * | 2005-02-24 | 2007-11-22 | Boukharov Andrey A | Methods for genetic control of plant pest infestation and compositions thereof |
WO2007076524A2 (fr) * | 2005-12-29 | 2007-07-05 | Centocor, Inc. | Anticorps humains anti-il-23, compositions, procedes et utilisations afferents |
US20080095775A1 (en) * | 2006-06-13 | 2008-04-24 | Lewis Katherine E | Il-17 and il-23 antagonists and methods of using the same |
US20080095770A1 (en) * | 2006-08-09 | 2008-04-24 | Glycart Biotechnology Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
US20090175881A1 (en) * | 2006-08-11 | 2009-07-09 | Presta Leonard G | Antibodies to il-17a |
Non-Patent Citations (11)
Title |
---|
UMMC, Ulcerative colitis - Introduction, 2011 [online]. [Retrieved on 2011.06.03]. Retrieved from the Internet: <URL: http://www.umm.edu/patiented/articles/what_ulcerative_colitis_inflammatory_bowel_disease_00069_1.htm> * |
UniProt_ B9CX49, Dipeptide transport protein DppA1, 24 March 2009 [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/B9CX49> amino acid residues 118-126, that is 79.3% identical to the claimed SEQ ID NO: 18 * |
UniProt_A0D7C4, Chromosome undetermined scaffold_4, whole genome shotgun sequence, 28 November 2006 [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/A0D7C4> amino acid residues 62-71, that is 84.6% identical to the claimed SEQ ID NO: 15 * |
UniProt_A5ICM5, Putative uncharacterized protein, 26 June 2007 [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/A5ICM5> amino acid residues 419-427 that is 80.8% identical to the claimed SEQ ID NO: 8 * |
UniProt_A7XA61, DRF-like transcription factor DRFL2a, 23 October 2007 [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/A7XA61> amino acid residues 46-55, that is 86.5% identical to the claimed SEQ ID NO: 16 * |
UniProt_B4HXQ5, GM14347, 23 September 2008 [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/B4HXQ5> amino acid residues 128-137, that is 80% identical to the claimed SEQ ID NO: 12 * |
UniProt_C5A772, Permease, major facilitator superfamily, 28 July 2009 [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/C5A772> amino acid residues 89-100 that is 71.9% identical to the claimed SEQ ID NO: 2 * |
UniProt_Q5DF07, SJCHGC06558 protein, 29 March 2005 [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/Q5DF07> amino acid residues 275-284, that is 81.2% identical to the claimed SEQ ID NO: 13 * |
UniProt_Q8BCV6, Uncharacterized 55 kDa protein, 01 March 2003, [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/Q8BCV6> amino acid residues 260-266 that is 100% identical to the claimed SEQ ID NO: 6 * |
UniProt_Q8PJC9, Putative uncharacterized protein, 01 October 2001, [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/Q8PJC9> amino acid residues 12-18 that 100% identical to the claimed SEQ ID NO: 24 * |
UniProt_Q92TP0 (for C96025), Hypothetical exported protein, TonB-dependent receptor protein, 01 December 2001 [online]. [Retrieved on 2011.05.25]. Retrieved from the Internet: <URL: http://www.uniprot.org/uniprot/Q92TP0> amino acid residues 367-374 is 88.9% identical to the claimed SEQ ID NO: 7 * |
Also Published As
Publication number | Publication date |
---|---|
US8519107B2 (en) | 2013-08-27 |
EP2493506A2 (fr) | 2012-09-05 |
KR101836217B1 (ko) | 2018-03-08 |
CA2779257A1 (fr) | 2011-05-05 |
CL2012001141A1 (es) | 2012-11-30 |
EP2493506B1 (fr) | 2019-04-10 |
WO2011053763A3 (fr) | 2011-10-06 |
NI201200080A (es) | 2013-04-22 |
BR112012010280A2 (pt) | 2017-06-20 |
EA201290254A1 (ru) | 2012-12-28 |
ES2728115T3 (es) | 2019-10-22 |
CN102905727A (zh) | 2013-01-30 |
AU2010313304A1 (en) | 2012-05-24 |
IL219390A0 (en) | 2012-06-28 |
EP2493506A4 (fr) | 2013-11-20 |
GT201200132A (es) | 2014-01-17 |
AU2010313304B2 (en) | 2015-08-20 |
PE20121363A1 (es) | 2012-10-15 |
CA2779257C (fr) | 2019-03-12 |
CO6541541A2 (es) | 2012-10-16 |
MX2012005086A (es) | 2012-09-28 |
CN102905727B (zh) | 2016-12-07 |
ECSP12011871A (es) | 2012-08-31 |
KR20120102662A (ko) | 2012-09-18 |
JP2013509193A (ja) | 2013-03-14 |
JP5922025B2 (ja) | 2016-05-25 |
WO2011053763A2 (fr) | 2011-05-05 |
IL219390B (en) | 2019-01-31 |
CR20120298A (es) | 2014-01-09 |
BR112012010280B1 (pt) | 2020-09-24 |
US20110236390A1 (en) | 2011-09-29 |
NZ599737A (en) | 2015-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA029283B1 (ru) | Антагонисты il-17a | |
RU2742691C2 (ru) | Cd3-связывающий домен | |
DK1257648T4 (en) | Antagonistic selective binding agents of osteoprotegerin binding protein | |
JP6258194B2 (ja) | 抗神経成長因子抗体並びに前記の製造及び使用方法 | |
ES2704036T3 (es) | Anticuerpos anti-factor de crecimiento nervioso y procedimientos de preparación y uso de los mismos | |
JP6109571B2 (ja) | 複数種のCCケモカインと結合するantikine抗体 | |
US20180179294A1 (en) | Toll-like receptor 3 antagonists | |
JP2021533779A (ja) | 操作された二重特異性タンパク質 | |
EP1257648B2 (fr) | Agents de liaison selectifs antagonistes de proteine de liaison d'osteoprotegerine | |
CN109311997A (zh) | 抗axl拮抗抗体 | |
CN103601806B (zh) | Il-6结合分子 | |
JP5727463B2 (ja) | Toll様受容体3アンタゴニスト | |
JP2016500656A (ja) | 代謝性疾患及び心臓血管疾患を治療するためのtoll様受容体3アンタゴニスト | |
CN109929035A (zh) | 抗人ngf抗体及其制备方法和用途 | |
CN111819201A (zh) | Pd1结合剂 | |
BR112021004686A2 (pt) | proteínas de ligação de antígeno anti-flt3 melhoradas | |
CN109721656A (zh) | 靶向rankl的治疗性抗体 | |
WO2013039471A1 (fr) | Antagonistes du récepteur 3 de type toll utilisables en vue du traitement de maladies métaboliques et cardiovasculaires | |
TW202210513A (zh) | 抗igf-1受體人源化抗體 | |
WO2024153223A1 (fr) | Procédé de traitement du lupus érythémateux disséminé | |
JP2023504974A (ja) | 抗tirc7抗原結合タンパク質 | |
WO2015176104A1 (fr) | Protéines de liaison bak |